Blade Therapeutics to Present at the 2020 Stifel Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., November 9, 2020 – Blade Therapeutics today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present at the 2020 Stifel Virtual Healthcare Conference. The virtual session will take place on Monday, November 16, 2020, at 3:20 – 3:50 p.m. Eastern Time. A link to the live and archived webcast presentation can be accessed on the “News & Events” page of the Blade company website at https://www.blademed.com/news/events/.
About Blade Therapeutics
Blade Therapeutics is a private biopharmaceutical company founded on a commitment to revolutionize the treatment of debilitating, incurable fibrotic diseases that impact millions of people worldwide. The Company is an expert in novel biological pathways – including calpain and autotaxin / LPA biology – that are foundational to cell and tissue damage responses leading to fibrosis. Blade is advancing a robust pipeline of potential first- and best-in-class investigational therapies for diseases of lung (acute and chronic), liver and heart fibrosis, as well as neuro-degenerative diseases. This includes multiple small-molecule direct inhibitors of dimeric calpains and of autotaxin / LPA that offer distinct but complementary anti-fibrotic mechanisms.
Since its founding in 2015, the Company has raised approximately $90 million, including investments from Deerfield Management, MPM Capital, Pfizer Ventures, One Ventures, Osage University Partners and pharma strategic investments from Bristol-Myers Squibb and Novartis Institutes for Biomedical Research. The Company has assembled critical leadership expertise supplemented by a world-class network of scientific, pharmaceutical and clinical advisors to enable efficient and successful drug development. Visit www.blademed.com for more information.
Fibrosis is a complex, pathologic process involving the development of fibrous connective tissue (scarring) within various organs. This process may be triggered by a dysregulated response to cellular injury, inflammation, genetic signaling, metabolism or toxins. Once present, normal cellular function is impeded. Later-stage fibrotic disease is marked by poor outcomes and high morbidity and mortality. Diseases characterized by uncontrolled, progressive fibrosis include idiopathic pulmonary fibrosis (IPF), interstitial lung disease (ILD) and non-alcoholic steatohepatitis (NASH). New safe, well-tolerated therapies that provide robust attenuation of disease progression are urgently needed to address the high burden of fibrotic diseases.
Media Relations – Michael Blash
Investors Relations – Krishna Gorti, M.D.